BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

960 related articles for article (PubMed ID: 23065959)

  • 21. Normal dynamic MRI enhancement patterns of the upper abdominal organs: gadoxetic acid compared with gadobutrol.
    Kühn JP; Hegenscheid K; Siegmund W; Froehlich CP; Hosten N; Puls R
    AJR Am J Roentgenol; 2009 Nov; 193(5):1318-23. PubMed ID: 19843748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis.
    Grazioli L; Bondioni MP; Haradome H; Motosugi U; Tinti R; Frittoli B; Gambarini S; Donato F; Colagrande S
    Radiology; 2012 Feb; 262(2):520-9. PubMed ID: 22282184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations.
    de Campos RO; Heredia V; Ramalho M; De Toni MS; Lugo-Somolinos A; Fuller ER; Semelka RC
    AJR Am J Roentgenol; 2011 Mar; 196(3):545-52. PubMed ID: 21343495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of nonischemic fibrosis in hypertrophic cardiomyopathy: comparison of gadopentetate dimeglumine and gadobenate dimeglumine for enhanced cardiovascular magnetic resonance imaging.
    Rudolph A; von Knobelsdorff-Brenkenhoff F; Wassmuth R; Prothmann M; Utz W; Schulz-Menger J
    J Magn Reson Imaging; 2014 May; 39(5):1153-60. PubMed ID: 24151119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
    Khouri Chalouhi C; Vernuccio F; Rini F; Duca P; Tuscano B; Brancatelli G; Vanzulli A
    Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of increasing the flip angle during the hepatocyte phase of gadobenate dimeglumine-enhanced 1.5T MRI in cirrhotic patients with hepatocellular carcinoma.
    Lee EJ; Kim DJ; Cho ES; Kim KA
    J Magn Reson Imaging; 2016 Mar; 43(3):713-9. PubMed ID: 26290384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the Enhancement Pattern of Hepatic Hemangioma on Magnetic Resonance Imaging Performed With Gd-EOB-DTPA Versus Gd-BOPTA.
    Vernuccio F; Bruno A; Costanzo V; Bartolotta TV; Vieni S; Midiri M; Salvaggio G; Brancatelli G
    Curr Probl Diagn Radiol; 2020; 49(6):398-403. PubMed ID: 31253462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions.
    Pirovano G; Vanzulli A; Marti-Bonmati L; Grazioli L; Manfredi R; Greco A; Holzknecht N; Daldrup-Link HE; Rummeny E; Hamm B; Arneson V; Imperatori L; Kirchin MA; Spinazzi A
    AJR Am J Roentgenol; 2000 Oct; 175(4):1111-20. PubMed ID: 11000175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Half-dose gadobenate dimeglumine versus standard-dose gadodiamide in dynamic magnetic resonance imaging of non-cirrhotic livers: a retrospective intra-individual crossover comparison.
    Homayoon B; Diwakar H; Strovski E; Bakshi D; Harris AC; Thoeni RF; Chang SD
    Abdom Imaging; 2014 Oct; 39(5):955-62. PubMed ID: 24676875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
    Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A
    AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
    Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
    Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience.
    Park Y; Kim SH; Kim SH; Jeon YH; Lee J; Kim MJ; Choi D; Lee WJ; Kim H; Koo JH; Lim HK
    Korean J Radiol; 2010; 11(4):433-40. PubMed ID: 20592927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implication of small (<20 mm) enhancing hepatic nodules observed only during three-dimensional gadobenate dimeglumine-enhanced hepatic arterial-phase MRI of the hepatitis B virus-induced mild cirrhosis.
    Kim YK; Lee YH; Kwak HS; Kim CS; Han YM
    Clin Imaging; 2008; 32(6):453-9. PubMed ID: 19006774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
    Jeon TY; Kim SH; Lee WJ; Lim HK
    Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
    Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Focal nodular hyperplasia: intraindividual comparison of dynamic gadobenate dimeglumine- and ferucarbotran-enhanced magnetic resonance imaging.
    Marin D; Iannaccone R; Laghi A; Catalano C; Murakami T; Hori M; Kim T; Passariello R
    J Magn Reson Imaging; 2007 Apr; 25(4):775-82. PubMed ID: 17348002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM Multicenter Trial): CEUS vs. MRI--a prospective comparison in 269 patients.
    Seitz K; Bernatik T; Strobel D; Blank W; Friedrich-Rust M; Strunk H; Greis C; Kratzer W; Schuler A
    Ultraschall Med; 2010 Oct; 31(5):492-9. PubMed ID: 20652854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium.
    Bieze M; van den Esschert JW; Nio CY; Verheij J; Reitsma JB; Terpstra V; van Gulik TM; Phoa SS
    AJR Am J Roentgenol; 2012 Jul; 199(1):26-34. PubMed ID: 22733890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Dynamic MRI of the liver with parallel acquisition technique: characterization of focal liver lesions and analysis of the hepatic vasculature in a single MRI session].
    Heilmaier C; Sutter R; Lutz AM; Seifert B; Willmann JK
    Rofo; 2008 May; 180(5):440-8. PubMed ID: 18438745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.